Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-08-21 01:37Core Insights - Heng Rui Medicine (600276.SH) reported a total operating revenue of 15.761 billion yuan for the first half of 2025, an increase of 2.16 billion yuan compared to the same period last year, marking a 15.88% year-on-year growth [1] - The net profit attributable to shareholders reached 4.450 billion yuan, up by 1.018 billion yuan year-on-year, reflecting a 29.67% increase [1] - The net cash inflow from operating activities was 4.300 billion yuan, an increase of 1.268 billion yuan year-on-year, representing a 41.80% growth [1] Financial Performance - The latest debt-to-asset ratio stands at 6.14%, a decrease of 1.15 percentage points from the previous quarter and a reduction of 4.22 percentage points year-on-year [3] - The gross profit margin is reported at 86.58%, an increase of 1.41 percentage points from the previous quarter and 0.35 percentage points year-on-year [3] - The return on equity (ROE) is recorded at 7.61% [3] Earnings and Shareholder Information - The diluted earnings per share (EPS) is 0.70 yuan, an increase of 0.16 yuan year-on-year, reflecting a 29.63% growth [3] - The total asset turnover ratio is 0.28 times, while the inventory turnover ratio is 0.85 times, an increase of 0.03 times year-on-year, representing a 3.14% growth [3] - The number of shareholders is 364,700, with the top ten shareholders holding a total of 4.043 billion shares, accounting for 60.91% of the total share capital [3]